Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/23/23
End: 12/31/28
Due: 12/31/29
Phase: N/A
Priority: Normal
Start: 11/20/23
End: 11/30/27
Due: 11/30/28
Phase: N/A
Priority: Normal
Start: 02/23/17
End: 01/31/26
Due: 01/31/27
Phase: N/A
Priority: Normal
Start: 06/21/18
End: 05/31/25
Due: 05/31/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| VS-6766+Abema+Fulv in Met HR+/HER- BC | NCT05608252 | Adrienne G. Waks | user2@example.com | None | 2023-02-23 | 2028-12-31 | 2029-12-31 | - | - | 2025-07-14 |
| A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) | NCT06100874 | Adrienne G. Waks | user2@example.com | None | 2023-11-20 | 2027-11-30 | 2028-11-30 | - | - | 2025-07-14 |
| A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer | NCT02999477 | Adrienne G. Waks | user2@example.com | None | 2017-02-23 | 2026-01-31 | 2027-01-31 | - | - | 2025-07-14 |
| The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer | NCT03414658 | Adrienne G. Waks | user2@example.com | None | 2018-06-21 | 2025-05-31 | 2026-05-31 | - | - | 2025-07-14 |